Comparison

Lixisenatide vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Lixisenatide	VK2735
Germany	Prescription	Unapproved
JP	Prescription	—
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Lixisenatide and VK2735?: Lixisenatide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lixisenatide or VK2735?: The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lixisenatide and VK2735 in Germany and the United States?: Germany: Lixisenatide — Prescription, VK2735 — Unapproved. United States: Lixisenatide — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Lixisenatide

VK2735

Germany

Prescription

Unapproved

Prescription

—

United States

Unapproved

Frequently asked questions

What is the difference between Lixisenatide and VK2735?

Lixisenatide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lixisenatide or VK2735?

The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lixisenatide and VK2735 in Germany and the United States?

Germany: Lixisenatide — Prescription, VK2735 — Unapproved. United States: Lixisenatide — Unapproved, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.